Skip to main content
Midas Edge

Cadrenal Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

CVKD$1.37+39.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

Exhibit No.Description
3.1Amended and Restated Certificate of Incorporation (Incorporated by reference as Exhibit 3.3 to the Registration Statement on Form S-1 (File No. 333-267562) filed on September 22, 2022)
3.2Amended and Restated Bylaws (Incorporated by reference as Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-267562) filed on December 6, 2022)
3.3Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference as Exhibit 3.1 to the Current Report on Form 8-K filed on August 20, 2024)
4.1Form of New Warrant (incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K filed on April 1, 2026)
4.2Form of Placement Agent Warrant (incorporated by reference as Exhibit 4.2 to the Current Report on Form 8-K filed on April 1, 2026)
4.3Form of Pre-Funded Warrant (incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K filed on July 1, 2026)
4.4Form of Series C-1 Warrant (incorporated by reference as Exhibit 4.2 to the Current Report on Form 8-K filed on July 1, 2026)
4.5Form of Series C-2 Warrant (incorporated by reference as Exhibit 4.3 to the Current Report on Form 8-K filed on July 1, 2026)
4.6Form of Placement Agent Warrant (incorporated by reference as Exhibit 4.4 to the Current Report on Form 8-K filed on July 1, 2026)
10.1Form of Warrant Inducement Agreement (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on April 1, 2026)
10.2#Severance and Release Letter Agreement, dated June 3, 2026, between Cadrenal Therapeutics, Inc. and Matthew Szot (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on June 3, 2026)
10.3Master Services Agreement, dated August 21, 2024, between the Company and Lohman & Associates, Inc. (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on June 29, 2026)
10.4Statement of Work Number Five, effective as of June 25, 2026, pursuant to Master Services Agreement (incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K filed on June 29, 2026)
10.5Form of Securities Purchase Agreement (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on July 1, 2026)
10.6Form of Registration Rights Agreement (incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K filed on July 1, 2026)
10.7#Confidential Separation Agreement and General Release by and between Cadrenal Therapeutics, Inc. and James J. Ferguson III (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on July 17, 2026)
31.1*Certification of the Principal Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*Certification of the Principal Financial Officer and Principal Accounting Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*Certification by the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*Certification by the Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSInline XBRL Instance*
101.SCHInline XBRL Taxonomy Extension Schema*
101.CALInline XBRL Taxonomy Extension Calculation*
101.DEFInline XBRL Taxonomy Extension Definition*
101.LABInline XBRL Taxonomy Extension Labeled*
101.PREInline XBRL Taxonomy Extension Presentation*
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
  • Filed herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.